ArticleMolecules (Basel, Switzerland)2025
The Proteomic Analysis of Platelet Extracellular Vesicles in Diabetic Patients by nanoLC-MALDI-MS/MS and nanoLC-TIMS-MS/MS.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Integrating mass spectrometry-based multi-omic signatures of extracellular vesicles: from discovery to clinical translation.Clinical & translational immunology · 2026Review
- The Role of LVV-H7 in Alcohol-Induced Reward Mechanisms.Addiction biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet extracellular vesicles (PEVs) are emerging as key biomarkers in diabetes mellitus (DM), reflecting altered platelet function and coagulation pathways. This study compares two proteomic techniques-nanoLC-MALDI-MS/MS and nanoLC-TIMS-MS/MS-for analyzing PEVs in diabetic patients, to assess their potential for biomarker discovery. PEVs were isolated from platelet-rich plasma and characterized using tunable resistive pulse sensing (TRPS), Fourier-transform infrared (FTIR) spectroscopy, and transmission electron microscopy (TEM). Proteomic analyses identified significant differences in protein expression between diabetic and non-diabetic individuals, with nanoLC-TIMS-MS/MS demonstrating superior sensitivity by detecting 97% more unique proteins than nanoLC-MALDI-MS/MS. Key differentially expressed proteins included apolipoproteins and oxidative stress markers, which may contribute to platelet dysfunction and cardiovascular complications in DM. Sex-specific variations in protein expression were also observed, highlighting potential differences in disease progression between male and female patients. The integration of advanced proteomic methodologies provides novel insights into the role of PEVs in diabetes pathophysiology, underscoring their diagnostic and therapeutic potential. These findings pave the way for improved biomarker-based strategies for early detection and monitoring of diabetic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.